SQI Buying Microarray Firm Scienion for $15.6M, and Stock
July 05, 2011
SQI Buying Microarray Firm Scienion for $15.6M, and Stock
The proposed purchase is anticipated to further push SQI's entry into the market for technologies for multiplexed protein, antibody, antigen, and molecular microarrays.
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.
Related Stories
- Array-Based Tests Advance as Dx Firms Engage FDA, Raise Capital, Report Revenue Growth
May 15, 2012 / BioArray News - SQI Diagnostics Abandons Bid to Acquire Scienion, Withdraws IPO
October 11, 2011 / BioArray News - SQI Diagnostics Amends Purchase Deal of Scienion to Push Back Termination Date
September 27, 2011 / GenomeWeb Daily News - PGXL, AutoGenomics Partner on Personalized Medicine
April 1, 2011 / GenomeWeb Daily News - Canada Clears SQI’s Celiac Assay
September 21, 2010 / GenomeWeb Daily News